Navigation Links
Inflammatory mediator enhances plaque formation in Alzheimer’s disease
Date:9/7/2011

Alzheimer's disease (AD) is a devastating neurodegenerative disorder that causes progressive cognitive impairment and memory loss. Now, a new study published by Cell Press in the September 8 issue of the journal Neuron identifies a previously unrecognized link between neuroinflammation and the classical pathological brain changes that are the hallmark of the disease. In addition, the research identifies a new potential therapeutic target for AD.

AD is characterized by abnormal accumulation of amyloid Β (AΒ) protein plaques and neurofibrillary tangles of tau protein in the brain. In addition to these classical hallmarks, neuroinflammation has also been identified as a major component of the disease. Previous research has suggested that AD associated inflammation increases the inducible nitric oxide synthase (NOS2) in neurons and support cells. Importantly, NOS2 leads to generation of nitric oxide (NO) which has been linked with neurodegeneration.

"One of the fingerprints of NO is tyrosine nitration, a posttranslational protein modification that can induce structural changes leading to protein aggregation," explains senior study author, Dr. Michael T. Heneka, from the University of Bonn in Germany. "Since there is so far no mechanistic explanation how expression of NOS2 and the subsequent production of NO and its reaction products modulate AΒ and thereby the progression of AD, we speculated that nitration of AΒ might contribute to AD pathology."

In their study, first author Dr. Markus P. Kummer and colleagues discovered that AΒ is a novel NO target. They observed nitrated AΒ in AD and AD mouse models and found that this modification accelerated the deposition of human AΒ. Importantly, reduction of NOS2 reduced AΒ deposition and memory deficits in a mouse model of AD. Further, nitrated AΒ induced the formation of amyloid plaques when injected into the brains of mice with genetic mutations associated with AD.

"Taken together, our results identify a novel modification of AΒ, tyrosine nitration, and propose a causative link between the AΒ cascade, activation of NOS2, and the subsequent increase in its reaction product nitric oxide during AD," concludes Dr. Heneka. "We think that nitrated AΒ may serve as marker of early AΒ plaque formation. More importantly, it may be a promising target for an AD therapy, and that application of specific inhibitors of NOS2 may therefore open a new therapeutic avenue in AD."


'/>"/>

Contact: Elisabeth (Lisa) Lyons
elyons@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Related medicine news :

1. Inflammatory Bowel Ups Risk for Blood Clots
2. NIH grant will create behavioral health registry for pediatric inflammatory bowel disease
3. Prozac and Celexa exhibit anti-inflammatory effects
4. Physician's Pain Relief Cream Includes Patented Anti-inflammatory in New Formula
5. Feedback loop explains inflammatory effect on intestinal lining
6. Study Details Machinery of Immune Protection Against Inflammatory Diseases Like Colitis
7. Two New Phytochemicals with Anti-Inflammatory Activity Found in Noni Fruit
8. New research reinforces anti-inflammatory properties of tart cherries
9. First Annual Observance of World IBD Day Draws Awareness to Growing Global Incidence of Inflammatory Bowel Disease
10. POP ROCK BAND Honor Society Drummer Advocates for Inflammatory Bowel Disease Patients on Capitol Hill in Conjunction with World IBD Day
11. Crohn's & Colitis Foundation National Event Helping Women Manage Inflammatory Bowel Disease: Two Women Physician Experts and Researchers in IBD on Interactive Webcast/Teleconference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology: